HDL FORUM

Apolipoprotein A-II is atheroprotective

Fri, 13 Jun 2008 00:00:00 e

Apolipoprotein A-II, a component of high-density lipoprotein (HDL), was shown to be anti-atherogenic in one of the largest studies to date, based on the EPIC-Norfolk cohort. HDL Forum Editor0 Professor Kerry-Anne Rye discusses these data and their implications.

High-density lipoprotein and inflammation - new insights

Tue, 14 Oct 2008 00:00:00 e

Atherosclerosis is a chronic inflammatory disease.The anti-inflammatory properties of HDL and their main apolipoprotein, apoA-I, is a topic that is currently attracting considerable interest.

Ethnic differences in antipsychotic effects on HDL

Mon, 22 Dec 2008 00:00:00 e

Evidence from the US CATIE Schizophrenia Study suggests that there may be underlying racial differences in how antipsychotic treatment influences high density lipoprotein (HDL) cholesterol. In this trial, white subjects who took perphenzaine and non-whites who took ziprasidone showed an increase in HDL cholesterol levels. These findings may have implications for choice of medication in patients at high cardiometabolic risk.

CETP genotypes, HDL cholesterol and coronary risk

Tue, 14 Oct 2008 00:00:00 e

A meta-analysis including data from nearly 114,000 healthy subjects and over 27,000 coronary cases reported in the Journal of the American Medical Association showed an association between three genotypes of cholesteryl ester transfer protein (CETP), moderate increases in high-density lipoprotein (HDL) cholesterol and coronary risk. These data suggest that the presence of these CETP genetic variants may confer slightly reduced coronary risk. The study was reviewed by HDL Forum Editor, Professor John Chapman.

Thompson A, Di Angelantonio E, Sarwar N et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88.